Kopran has reported a 70% growth in net profits in the first quarter of the current year despite a 5% reduction in turnover. While other income (which accounted for 21% of the PBT) was partly responsible for the growth the main reason for the demerger was the spin off the low margin yielding semi synthetic penicillin (SSP) business into a separate company last year.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (m) (eoy)
Diluted no. of shares (m)
Diluted Earnings per share*
The company had a joint venture with Synpac Pharma one of the largest single site penicillin manufacturers in the world. The world over it has been seen that as far as semi synthetic penicillin (SSP) is concerned it is the only the integrated players who have emerged successful.
To the shareholders of Kopran, one share in the new company KDL Biotech was given for every two shares that they held in Kopran Ltd. The latter is now basically focused on five therapeutic areas: cardiology, respiratory, gastrointestinal, antibiotics and pain management. Of the company’s domestic dosage sales around 20% accrues from products under the DPCO.
The stock quotes at Rs 84 (its 52 week low) which implies an earning multiple of 7.8 times its first quarter annualised earnings. The market, however, does not seem to be appreciating the steps that the management has taken to improve transparency and shareholder value.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407